Usage of Barium Titanate in Fabric Coating and Investigation of Some Properties

Rumeysa Celen,Gizem Manasoglu,Yusuf Ulcay,Mehmet Kanik 한국섬유공학회 2021 Fibers and polymers Vol.22 No.5

In this study, nano-sized barium titanate powder was applied for the first time to polyester woven fabrics by knifecoating at three different concentration rates. Some physical (thickness, mass per unit area, bending rigidity, air permeabilityand tear strength) properties, electromagnetic shielding efficiency and solar (transmittance, reflectance) properties of sampleswere presented. The samples were also characterized by Fourier transform infrared spectroscopy and scanning electronmicroscopy. Electromagnetic shielding effectiveness of the fabrics was determined according to the ASTM D4935-10standard by using a coaxial transmission line measurement technique in the frequency range of 15-3000MHz. The solarproperties were measured according to EN14500 standard using a UV/VIS/NIR spectrophotometer and results were calculatedaccording to EN 410 standard. Results revealed that the electromagnetic shielding effectiveness and solar reflectance propertyof samples improved with increasing barium titanate concentration.

Examination of protective and therapeutic effects of ruscogenin on cerulein-induced experimental acute pancreatitis in rats

Gulcin Ercan,Rumeysa İlbar Tartar,Ali Solmaz,Osman Bilgin Gulcicek,Onur Olgac Karagulle,Serhat Meric,Huseyin Cayoren,Ramazan Kusaslan,Ahu Kemik,Damla Gokceoglu Kayali,Sule Cetinel,Atilla Celik 대한외과학회 2019 Annals of Surgical Treatment and Research(ASRT) Vol.97 No.6

Purpose: To determine the potential protective and therapeutic effects and action mechanism of ruscogenin on ceruleininduced acute pancreatitis (AP) model in rats. Methods: Overall, 32 rats were attenuated to the sham (2-mL/kg/day isotonic solution for 4 weeks), control (20-μg/kg cerulein-induced AP for 12 hours), prophylaxis groups (cerulein-induced AP following 3-mL/kg/day ruscogenin for 4 weeks) and treatment (3-mL/kg/day ruscogenin following cerulein-induced AP for 12 hours). Blood samples were collected for biochemical analysis of nitric oxide synthase 1 (NOS1/neuronal NOS), malondialdehyde (MDA) and intercellular adhesion molecule 1 (ICAM-1). After sacrification, pancreas tissues were collected and prepared for light microscopic (hematoxylin and eosin), immunohistochemical (nuclear factor kappa B) and biochemical analysis (tumor necrosis factor-alpha [TNF-α], interleukin-6 and 1β [IL-6 and IL-1β], CRP, high-sensitivity CRP [hs-CRP] amylase, lipase, and ICAM-1). Ultrastructural analysis was performed by transmission electron microscopy. Results: The protective and therapeutic actions of ruscogenin were accomplished by improvements in histopathology, by decreasing blood cytokine levels of CRP, hs-CRP levels, TNF-α, IL-6, IL-1β, ICAM-1, by reducing the pancreatic enzymes amylase and lipase in blood, and by suppressing the expression of nuclear factor kappa B, ICAM-1, and NOS-1, but not MDA in pancreatic tissues. Ruscogenin also improved cerulein-induced ultrastructural degenerations in endocrine and exocrine cells, especially in treatment group. Conclusion: The present findings have demonstrated the beneficial protective and therapeutical effects of ruscogenin, nominating it as a highly promising supplementary agent to be considered in the treatment of AP, and even as a protective agent against the damages induced by disease

Does Beta-blocker Therapy Improve the Survival of Patients with Metastatic Non-small Cell Lung Cancer?

Aydiner, Adnan,Ciftci, Rumeysa,Karabulut, Senem,Kilic, Leyla Asian Pacific Journal of Cancer Prevention 2013 Asian Pacific journal of cancer prevention Vol.14 No.10

Aim: To determine whether beta-blockers (BBs) improve the overall survival (OS) of patients with metastatic non-small cell lung cancer (NSCLC). Materials and Methods: The medical charts of 107 patients with metastatic NSCLC were retrospectively assessed. Thirty-five patients (BB group) using BBs during chemotherapy (CT) were compared with 72 controls [control=(C) group] who did not use BBs following the diagnosis of NSCLC. The histological tumor subtype, performance status (ECOG), age, gender, smoking status, comorbidities, other medications and chemotherapeutics that were received in any line of treatment were recorded. We compared the overall survival (OS) of the patients in the BB and C groups. Results: The mean age of the patients was 61 years (range 42-81 years) and all patients were administered CT. The BB group was more likely to have HT and IHD and was more likely to use RAS blockers (p<0.01 for all) compared with the C group, as expected. The mean follow-up time was 17.8 months (range 1-102 months) for the entire group. The most commonly prescribed BB agent was metoprolol (80% of cases). At the time of the analysis, 74 (69%) of all patients had died. In the univariate analysis the median overall survival (OS) was 19.25 (${\pm}2.87$) months (95%CI: 13.62-24.88) in the BB group and 13.20 (${\pm}2.37$) months (95%CI: 8.55-17.85) in the C group (p=0.017). However, the benefit of BBs on survival disappeared in the multivariate analysis. Conclusions: The use of BBs during CT may be associated with an improved OS for patients with metastatic NSCLC.

Intolerance to Sunitinib Treatment in Hemodialysis Patients With Metastatic Renal Cell Carcinoma

Ibrahim Yildiz,Fatma Sen,Leyla Kilic,Rumeysa Ciftci,Mert Basaran 대한비뇨의학회 2014 Investigative and Clinical Urology Vol.55 No.1

Sunitinib is a multiple tyrosine kinase receptor inhibitor that is approved for the treatmentof metastatic renal cell carcinoma (RCC). However, neither an appropriate dosenor dosing schedule of sunitinib has yet been established for patients with metastaticRCC who are on hemodialysis. Here, we report on two hemodialysis patients who receivedsunitinib to treat metastatic RCC. Sunitinib was planned to be administeredat a dosage of 25 mg/d for 4 of every 6 weeks. Although sunitinib toxicity was manageablein one patient, disease progression occurred after 4 months of treatment. In the secondpatient, acute pulmonary edema, caused by uncontrolled hypertension, developed onthe 15th day of sunitinib therapy and the drug had to be discontinued. Sunitinib is thusnot well tolerated in a hemodialysis setting. Close monitoring of toxicity and dose manipulationmay be required if such therapy is attempted.

Evaluation of prophylactic and therapeutic effects of ruscogenin on acute radiation proctitis

Erkan Yavuz,Onur Olgac Karagulle,Gulcin Ercan,Atilla Celik,Hakan Yigitbas,Busra Yaprak Bayrak,Rumeysa Tartar,Ramazan Kusaslan,Yuksel Altine,Osman Bilgin Gulcicek 대한외과학회 2018 Annals of Surgical Treatment and Research(ASRT) Vol.94 No.4

Purpose: Radiation proctitis (RP) is inflammation and damage to the rectum, manifested secondary to ionizing radiation utilized for treatment. In this study, we evaluated the anti-inflammatory therapeutical and protective effects of ruscogenin in a model of acute RP. Methods: Thirty-two Sprague-Dawley rats were divided into 4 groups (n = 8) as sham, control, treatment, and prophylaxis groups. Prophylaxis group and treatment group were dosed ruscogenin by oral gavage for 14 days pre- and postradiation. At the end of the 28th day, all subjects were sacrificed. Results: Histopathological analysis showed a significant increase in cryptitis abscess, cryptitis and reactive atypia, and depth of lymphocytic infiltration of the control group, compared to the other groups (P < 0.05), while treatment and prophylaxis groups showed significant decreases (P < 0.05). Immunohistochemical analysis indicated that immunoreactivity were significantly higher in control group (P < 0.05, P < 0.001, and P < 0.01, respectively), but vice versa for treatment and prophylaxis groups. There was not any significant difference for fibroblast growth factor 2 immunoreactivity. The epithelium of control rectums indicated an increase in TNF-α immunoreactivity while other groups had significant decrease (P < 0.01). Electron microscopical findings were parallel to light microscopy. Conclusion: In this study, ruscogenin was observed to be effective on prophylaxis or treatment of acute RP. Although there are various reports on the treatment of the rectum damaged by acute RP in the literature, this could be the first study since there is no research indicating the ultrastructural effect of ruscogenin.